Business Daily Media

Times Advertising

.

China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter

  • Written by ACN Newswire - Press Releases
HONG KONG, Jan 28, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao") received an approval letter from the National Medical Products Administration for a clinical trial of the Company's LY007

Read more //?#

Pre-Budget Expectations

“Australian corporates and SMBs are under pressure. Competition from global players is intensifying, margins are under strain, and technology adop...

“Time is running out to get Payday ready,” Brighter Super urges

Superannuation fund Brighter Super is encouraging business owners to prepare now for Payday Super, ahead of the new laws taking effect from 1 July...

PayNuts Unveils Expanded Integrated Solutions and Refreshed Brand to Support Australian SMEs

PayNuts, one of Australia’s fastest-growing payment service providers, has unveiled a refreshed brand identity and an expanded suite of integrated b...

BizCover Brings Australia’s First AI-Based Insurance Quotes to ChatGPT

Australian small business owners can now receive and compare business insurance quotes directly inside ChatGPT, in a move that signals a major shi...

VistaPrint Research Reveals Australian Small Businesses Face a Succession Cliff

With only 16% of retiring small businesses having a succession plan, tens of thousands risk closure as one in three owners nears retirement.  Ne...

Corporate volunteering grows up: how companies are shifting to meaningful, community-led impact

As workplaces settle into the new year and look for ways to strengthen culture, capability and connection, experts say corporate volunteering is e...